Cargando…

Unleashing the power of NK cells in anticancer immunotherapy

Due to their physiological role in removing damaged cells, natural killer (NK) cells represent ideal candidates for cellular immunotherapy in the treatment of cancer. Thereby, the cytotoxicity of NK cells is regulated by signals on both, the NK cells as well as the targeted tumor cells, and the inte...

Descripción completa

Detalles Bibliográficos
Autores principales: Vogler, Meike, Shanmugalingam, Senthan, Särchen, Vinzenz, Reindl, Lisa Marie, Grèze, Victoria, Buchinger, Leon, Kühn, Michael, Ullrich, Evelyn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8843917/
https://www.ncbi.nlm.nih.gov/pubmed/34374809
http://dx.doi.org/10.1007/s00109-021-02120-z
_version_ 1784651369326575616
author Vogler, Meike
Shanmugalingam, Senthan
Särchen, Vinzenz
Reindl, Lisa Marie
Grèze, Victoria
Buchinger, Leon
Kühn, Michael
Ullrich, Evelyn
author_facet Vogler, Meike
Shanmugalingam, Senthan
Särchen, Vinzenz
Reindl, Lisa Marie
Grèze, Victoria
Buchinger, Leon
Kühn, Michael
Ullrich, Evelyn
author_sort Vogler, Meike
collection PubMed
description Due to their physiological role in removing damaged cells, natural killer (NK) cells represent ideal candidates for cellular immunotherapy in the treatment of cancer. Thereby, the cytotoxicity of NK cells is regulated by signals on both, the NK cells as well as the targeted tumor cells, and the interplay and balance of these signals determine the killing capacity of NK cells. One promising avenue in cancer treatment is therefore the combination of NK cell therapy with agents that either help to increase the killing capacity of NK cells or sensitize tumor cells to an NK cell-mediated attack. In this mini-review, we present different strategies that can be explored to unleash the potential of NK cell immunotherapy. In particular, we summarize how modulation of apoptosis signaling within tumor cells can be exploited to sensitize tumor cells to NK cell-mediated cytotoxicity.
format Online
Article
Text
id pubmed-8843917
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-88439172022-02-23 Unleashing the power of NK cells in anticancer immunotherapy Vogler, Meike Shanmugalingam, Senthan Särchen, Vinzenz Reindl, Lisa Marie Grèze, Victoria Buchinger, Leon Kühn, Michael Ullrich, Evelyn J Mol Med (Berl) Review Due to their physiological role in removing damaged cells, natural killer (NK) cells represent ideal candidates for cellular immunotherapy in the treatment of cancer. Thereby, the cytotoxicity of NK cells is regulated by signals on both, the NK cells as well as the targeted tumor cells, and the interplay and balance of these signals determine the killing capacity of NK cells. One promising avenue in cancer treatment is therefore the combination of NK cell therapy with agents that either help to increase the killing capacity of NK cells or sensitize tumor cells to an NK cell-mediated attack. In this mini-review, we present different strategies that can be explored to unleash the potential of NK cell immunotherapy. In particular, we summarize how modulation of apoptosis signaling within tumor cells can be exploited to sensitize tumor cells to NK cell-mediated cytotoxicity. Springer Berlin Heidelberg 2021-08-09 2022 /pmc/articles/PMC8843917/ /pubmed/34374809 http://dx.doi.org/10.1007/s00109-021-02120-z Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Review
Vogler, Meike
Shanmugalingam, Senthan
Särchen, Vinzenz
Reindl, Lisa Marie
Grèze, Victoria
Buchinger, Leon
Kühn, Michael
Ullrich, Evelyn
Unleashing the power of NK cells in anticancer immunotherapy
title Unleashing the power of NK cells in anticancer immunotherapy
title_full Unleashing the power of NK cells in anticancer immunotherapy
title_fullStr Unleashing the power of NK cells in anticancer immunotherapy
title_full_unstemmed Unleashing the power of NK cells in anticancer immunotherapy
title_short Unleashing the power of NK cells in anticancer immunotherapy
title_sort unleashing the power of nk cells in anticancer immunotherapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8843917/
https://www.ncbi.nlm.nih.gov/pubmed/34374809
http://dx.doi.org/10.1007/s00109-021-02120-z
work_keys_str_mv AT voglermeike unleashingthepowerofnkcellsinanticancerimmunotherapy
AT shanmugalingamsenthan unleashingthepowerofnkcellsinanticancerimmunotherapy
AT sarchenvinzenz unleashingthepowerofnkcellsinanticancerimmunotherapy
AT reindllisamarie unleashingthepowerofnkcellsinanticancerimmunotherapy
AT grezevictoria unleashingthepowerofnkcellsinanticancerimmunotherapy
AT buchingerleon unleashingthepowerofnkcellsinanticancerimmunotherapy
AT kuhnmichael unleashingthepowerofnkcellsinanticancerimmunotherapy
AT ullrichevelyn unleashingthepowerofnkcellsinanticancerimmunotherapy